Answers are grounded in this paper and cite their sources.
Notice of update The DDG clinical practice guidelines are updated regularly during the second half of the calendar year. Please ensure that you read and cite the respective current version. UPDATES TO CONTENT AND DIFFERENT RECOMMENDATIONS COMPARED TO THE PREVIOUS YEAR’S VERSION Change 1: [ Tab. 3 ] The “Erectile dysfunction” column under “Therapy” has been supplemented with “Intraurethral alprostadil gel”. Supporting reference: EAU Guidelines on Sexual and Reproductive Health 2024 https://uroweb.org/guidelines/sexual-and-reproductive-health Tab. 3 Clinically important manifestations, associated diagnostics and special therapy of autonomic diabetic neuropathy in diabetes mellitus. Data according to [ 2 ] [ 7 ]. Organ manifestations and clinical picture Examination methods Therapy Cardiovascular system Resting tachycardia Reduced heart rate variability Orthostatic hypotension Exercise intolerance (inadequate increase of heart rate and blood pressure during physical activity) Perioperative instability with frequent drops in blood pressure and heart rate Reduced or absent perception of myocardial ischaemia during physical activity Silent myocardial infarction or myocardial infarction with few symptoms Prolongation of the QT interval Sudden cardiac death Basic diagnostics HRV while breathing deeply and after change of position Orthostatic test Further diagnosticsAutonomic function tests (test battery): Resting HRV (frequency and time domain) Exhalation/inhalation ratio while breathing deeply Max/min 30:15-ratio Valsalva ratio (Valsalva manoeuvre) Orthostatic test 24-h HRV, syncope work-up Cardiovascular autonomic neuropathy In general, no special treatment necessary (important: diagnosis and therapy of coronary heart disease and heart failure) For sinus tachycardia cardioselective beta-blockers Orthostatic hypotension General measures: liberal salt intake, physical training, compression stockings, avoidance of hypotensive medications Medications with short half-lives that increase blood pressure (Midodrine) Fludrocortisone (start with a low dose) Gastrointestinal tract All gastrointestinal manifestations Basic GI tract diagnostics: Medical history Exclusion of structural and infectious diseases Dysphagia and reflux disease Further diagnostics: Stage 1: Esophagogastroduodenoscopy Other imaging examinations, as applicable Stage 2: Oesophagus manometry 24-h pH monitoring with/without impedance measurement Dysphagia : General measures: prokinetic agents in individual cases Reflux : Proton-pump inhibitors Diabetic gastropathy (dyspepsia, postprandial hypoglycaemia) Stage 1: Esophagogastroduodenoscopy Abdominal sonography If necessary, other imaging examinations Laboratory tests Stage 2: Gastric emptying scintigraphy 13 C-octanoic acid breath test (solid food), 13 C-acetate breath test (liquids) Gastroparesis (gastropathy): Dietary change: frequent, small, low-fibre and low-fat meals Adjust injection-to-meal interval Prokinetic agents (all off-label): Metoclopramide, domperidone, possibly prucalopride, erythromycin for severe refractory symptoms Antiemetics can be added to the symptomatic therapy of nausea and vomiting (antihistamines, 5-HT3-antagonists), as applicable Gastric electrical stimulation (“gastric pacemaker”) Jejunal feeding tube Parenteral nutrition Diabetic cholecystopathy Laboratory tests, abdominal sonography Cholecystectomy for symptomatic cholecystolithiasis as needed Diabetic diarrhoea (enteropathy) and exocrine pancreatic insufficiency Stage 1: Endoscopy Abdominal sonography Laboratory tests, including examination of stool for pathogenic organisms If necessary, other imaging examinations Stage 2: Lactose/fructose/sorbitol hydrogen breath test Glucose hydrogen breath test Faecal elastase-1, if necessary Lactulose hydrogen breath test, if necessary D-xylose absorption test, if necessary Diarrhoea: Bulking agents Loperamide Cholestyramine Clonidine Octreotide In case of bacterial overgrowth of the small intestine: broad-spectrum antibiotics, e. g. Rifaximin (off-label use) for 10 days with medicinal yeast (e. g. Perenterol); Severe exocrine pancreatic insufficiency Pancreatic enzymes Diabetic constipation (hypomotility of the colon) Stage 1: Digital rectal examination Ileocolonoscopy Laboratory tests Abdominal sonography, if necessary If necessary, other imaging examinations Stage 2: (MRI) defecography Anorectal manometry Hinton test Neurological examinations Constipation: Sufficient liquid, fibre and physical activity Gelling agents (pectins, psyllium preparations) Fibre-rich foods (e. g. wheat bran, linseed) Laxatives (e. g. sodium picosulfate, bisacodyl, macrogol, lactulose/lactitol) depending on tolerance and efficacy Biofeedback for rectal emptying disorder, if necessary Prucalopride for delayed transit (a prokinetic agent, approved for laxative-refractory constipation) Diabetic faecal incontinence Stage 1: Digital rectal examination Rectal endosonography (MRI) defecography Stage 2: Anorectal manometry Neurological examinations, if necessary Faecal incontinence: Antidiarrheal medications Pelvic floor gymnastics Biofeedback Sacral nerve stimulation in refractory cases, if necessary Urogenital tract Diabetic cystopathy (bladder emptying dysfunction) Basic diagnostics Micturition diary over 48 h Cystopathy: Behavioural changes Electrical stimulation Biofeedback Antimuscarinic drugs Beta-3 adrenergic receptor agonists Alpha receptor blockers Antibiotic therapy, as applicable Bladder neck incision Self-catheterisation Suprapubic cystostomy Further diagnostics Specific questionnaire (e. g. International Prostate Symptom Score (IPSS)) questionnaire Uroflowmetry Residual urine measurement Digital rectal examination for men Urodynamic testing, as applicable Erectile dysfunction Basic diagnostics Stage 1: Sexual history, IIEF-5 Laboratory tests Total testosterone (optional free testosterone), prolactin, FSH, LH Stage 2 (optional): Test with a PDE-5 inhibitor (sildenafil, vardenafil, tadalafil, avanafil) Erectile dysfunction: Avoidance of medication side effects (caused by antihypertensives, tranquilisers, antidepressants) 1) Step: Phosphodiesterase-5 inhibitors (sildenafil, tadalafil, vardenafil, avanafil) 2. Step: Erection aid system (vacuum pump) Corpus cavernosum auto-injection therapy Intraurethral alprostadil gel 3. Step: Corpus cavernosum implant Further diagnostics Stage 3 (only if surgical therapy is planned/indicated): Intracavernosal injection test Doppler/duplex sonography Cavernosometry/cavernosography Nocturnal tumescence measurement Hypogonadism: Testosterone substitution Neuroendocrine system (endocrine dysfunction) Hypoglycaemia-associated autonomic dysfunction Blunted or absent hormonal counterregulation Impaired hypoglycaemia perception Increased glucose threshold for hypoglycaemia symptoms at falling blood glucose Decreased catecholamine secretion when standing or upon physical exertion Tight blood glucose control (in particular self-monitoring), in particular during the night Avoidance of symptomatic and asymptomatic (often nocturnal) hypoglycaemia Hypoglycaemia awareness training (blood glucose awareness training; BGAT) Sudomotor and vasomotor functions Dyshidrosis, anhidrosis (“dry feet”) Gustatory sweating Sweat tests: QSART: Quantitative sudomotor axon reflex test TST: Thermoregulatory sweat test SSI: Silastic sweat imprint ACHSST: Acetylcholine sweatspot test Neuropad: Indicator plaster Sudoscan: Cutaneous electrochemical conductivity Topical agents containing fat or urea Avoidance of exposure to intense heat Prophylaxis in case of identified cause of sweating (dietary components) Anticholinergic drugs, clonidine (low dose) Topical glycopyrrolate cream In focal hyperhidrosis, botulinum toxin (Botox) can be tried Pupillomotor system Miosis Impaired pupil reflexes Reduced dark adaptation Clinical examination Infrared pupillography (constriction rate, dilatation rate, latency of pupillary light reflex) Advise patient of impaired dark adaptation and danger of night blindness Danger of glaucoma (check intraocular pressure) Respiratory system Central respiratory dysregulation with reduced respiratory drive in response to hypercapnia or hypoxemia Sleep apnoea syndrome Respiratory arrest Sleep laboratory, as applicable Continuous positive airway pressure (CPAP) therapy, as applicable HRV: heart rate variability; GI tract: gastrointestinal tract; IIEF-5: International Index of Erectile Function-5; FSH: follicle-stimulating hormone; LH: luteinising hormone; PDE5 inhibitors: phosphodiesterase-5 inhibitors; CPAP therapy: continuous positive airway pressure therapy; MRI: magnetic resonance imaging; h: hour. Publication History Article published online: 29 April 2025 © 2025. Thieme. All rights reserved. Georg Thieme Verlag KG Oswald-Hesse-Straße 50, 70469 Stuttgart, Germany
No takes yet. Share an insight, caveat, or question.
Ziegler et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: